India gets tough on generics quality issues and cancer drug prices
Even as more blood pressure drugs are being recalled in the USA after being found to contain trace amounts of a potentially cancer-causing ingredient, India’s...
Continue ReadingGUBBA PHARMA IN E NEWS
Suven plans to buy US-based Rising Pharmaceuticals’ assets
Suven Life Sciences through its joint venture partner, Shore Suven Pharma, has entered into a ‘stalking-horse’ asset purchase agreement to buy the assets of Aceto...
Continue Reading
USFDA lifts warning letter on Dr Reddy’s Duvvada plant in Andhra Pradesh
This is the second plant to come out of the warning letter after multiple inspections conducted by the US drug regulator. In a major relief to...
Continue Reading
Big relief for cancer patients: 30% margin on medicines to reduce prices, benefit poor
The healthcare industry has hailed the Modi government for capping 30 per cent margin on 42 drugs meant for the cancer patients. The industry insiders...
Continue Reading
Industry, regulator interaction needed for clarification on BA/BE submission norms
Even as the Central Drugs Standards Control Organisation (CDSCO) has set the ball rolling for BA/BE (bioavailability/ bioequivalence) submissions, the pharma and biotech industry in...
Continue Reading
Slayback Pharma announces approval of Hydroxyprogesterone Caproate Injection, USP 250 mg/ 1 mL in a single-dose vial, generic equivalent of Makena® Injection 250 mg/ 1 mL
Slayback Pharma LLC announced today that it has received final approval for Hydroxyprogesterone Caproate Injection, USP 250 mg/ 1 ml. This is the second ANDA...
Continue Reading